Search

Background: Migraine affects 1 billion people worldwide and > 30 million Brazilians; besides, it is an underdiagnosed and undertreated disorder., Objective: The need to disseminate knowledge about the prophylactic treatment of migraine is known, so the Brazilian Headache Society (SBCe, in the Portuguese acronym) appointed a committee of authors with the objective of establishing a consensus with recommendations on the prophylactic treatment of episodic migraine based on articles from the world literature as well as from personal experience., Methods: Meetings were held entirely online, with the participation of 12 groups that reviewed and wrote about the pharmacological categories of drugs and, at the end, met to read and finish the document. The drug classes studied in part II of this Consensus were: antihypertensives, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, calcium channel blockers, other drugs, and rational polytherapy., Results: From this list of drugs, only candesartan has been established as effective in controlling episodic migraine. Flunarizine, venlafaxine, duloxetine, and pizotifen were defined as likely to be effective, while lisinopril, enalapril, escitalopram, fluvoxamine, quetiapine, atorvastatin, simvastatin, cyproheptadine, and melatonin were possibly effective in prophylaxis of the disease., Conclusions: Despite an effort by the scientific community to find really effective drugs in the treatment of migraine, given the large number of drugs tested for this purpose, we still have few therapeutic options., Competing Interests: AOK: Speaker for Allergan, Ipsen Pharma, Merz, and Onyxcann Cantera; AT: Lilly, Teva, Ache, Supera, Allergan, and Novartis; CAPR: Teva, Novartis, Eli Lilly, Lundbeck, Aché, Apsen, and EJPC: Speaker for Novartis, Allergan, Libbs, and Lilly; EMS: Speaker for Libbs, Allergan, Novartis, Lilly, Lundbeck, and Teva. Advisory board: Allergan, Libbs, Teva, and Lundbeck; EMM: Speaker for Teva, Novartis, Eli Lilly, and Allergan; Advisory board: Libbs and Eli Lilly; GOMT: Speaker for Eli Lilly; HCC: Speaker for Allergan and Eli Lilly; ID, JAMJ, BAJS, MRCFF, MEJ, PFMMF, RPSN, YDF: No conflict of interests to declare; AJS: Speaker for Eli Lilly, Novartis, and Teva; JJC: Speaker for Eli Lilly, Novartis, Teva, and Libbs; Advisory board: Teva, Novartis, and Eli Lilly; JCS: Speaker for Teva, Novartis, and Allergan, Lilly; LCC: Speaker for Allergan, Novartis, and Sanofi; Advisory board: Allergan; LMB: Speaker for Novartis; LPQ: Speaker for Eli Lilly and Allergan; Advisory board: Eli Lilly and Teva; MNPS: Speaker for Eli Lilly, Novartis, Teva, Allergan, and Libbs; Advisory board: Sanofi, Eli Lilly, and Libbs; MENMC: Speaker for Eli Lilly, Novartis, Teva, and Allergan; Advisory board: Eli Lilly; MFPP: Grants from Fapesp and CNPq; personal fees from Allergan, Eurofarma, Eli Lilly, Libbs, Novartis, Pfizer, and Teva, during studies; PMP: Speaker for Novartis, Teva, Eli Lilly, and Libbs; Advisory board: Libbs; PSFS: Speaker for Teva, Novartis, Allergan, EMS, and Politec; Advisory board: Libbs and Eli Lilly; PAK: Fees for services from Libbs, Novartis, Allergan, Livanova, and Teva; PASRF: Speaker for Eli Lilly, Novartis, Allergan, and Libbs; Advisory board: Novartis, and Eli Lilly., (Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)

The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers., Competing Interests: AOK: speaker for Allergan, Ipsen Pharma, Merz, Onyxcann Cantera; ATNMC: speaker for Lilly, Teva, Ache, Supera, Allergan, Novartis; CAPR: speaker for Teva, Novartis, Eli Lilly, Lundbeck, Aché, Apsen, Cellera; EJP: speaker for Novartis, Allergan, Libbs, Lilly; EMS: speaker for Libbs, Allergan, Novartis, Lilly, Lundbeck, Teva; advisory board: Allergan, Libbs, Teva, Lundbeck; EMM: speaker for Teva, Eli Lilly, Allergan; advisory board: Libbs, Eli Lilly; GOMT: speaker for Eli Lilly; HCC: speaker for Allergan, Eli Lilly; JAS: speaker for Eli Lilly, Novartis, Teva; JJFC: speaker for Eli Lilly, Novartis, TEVA, Libbs; advisory board: TEVA, Novartis, Eli Lilly; JGS: speaker for Teva, Novartis, Allergan, Lilly; LCC: speaker for Allergan, Novartis, Sanofi; advisory board: Allergan; LMB: speaker for Novartis; LPQ: speaker for Eli Lilly, Allergan; advisory board: Eli Lilly, TEVA; MNPS: speaker for Lilly, Novartis, Teva, Allergan, Libbs; advisory board: Sanofi, Lilly, Libbs; MENMC: speaker for Eli Lilly, Novartis, Teva, Allergan; advisory board: Eli Lilly; MFPP: Grants from Fapesp and CNPq; personal fees from Allergan, Eurofarma, Eli Lilly, Libbs, Novartis, Pfizer, and Teva, during studies; PMP: speaker for Novartis, Teva, Eli Lilly, Libbs; advisory board: Libbs; PSFS: speaker for Teva, Novartis, Allergan, EMS, Politec; advisory board: Libbs, Lilly; PAK: fees for services to Libbs, Novartis, Allergan, Livanova, Teva; PASRF: speaker for Eli Lilly, Novartis, Allergan, Libbs; advisory board: Novartis, Eli Lilly; IF, JAMJ, JBAS, MRCFF, MEJ, PFMF, RPSN, YDF: no conflict of interests to declare., (Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)